Browsing by Author "Aydoğdu İ."
Now showing 1 - 16 of 16
Results Per Page
Sort Options
Item From bone marrow necrosis to gaucher disease; a long way to run; [Kemik İliği Nekrozundan Gaucher Hastalığı Tanısına Uzun Yol](Turkish Society of Hematology, 2015) Erdem N.; Çizmecioğlu A.; Aydoğdu İ.[No abstract available]Item A hundred years after the first article, a recollection: Cabot ring(Korean Association of Internal Medicine, 2016) Erdem N.; Berber İ.; Aydoğdu İ.; Sevinç A.[No abstract available]Item Serum zinc levels in iron deficient women: A case-control study; [Demir eksikliği anemisi olan kadınlarda serum çinko seviyesinin değerlendirilmesi: Olgu kontrol çalışması](Turkish Society of Hematology, 2016) Özhan O.; Erdem N.; Aydoğdu İ.; Erkurt A.; Kuku İ.Since similar symptoms and findings can be seen in the deficiencies of both iron and zinc, we aimed to evaluate the serum zinc levels of women with iron deficiency anemia (IDA). This study was conducted with women with iron deficiency and a healthy control group. When serum zinc levels were compared, they were found to be lower in the IDA group, which was statistically significant. With the help of these studies, iron and zinc treatment instead of only iron replacement may be considered in cases of iron deficiency. © 2016, Turkish Society of Hematology. All rights reserved.Item Pathological fracture in odontoid process in multiple myeloma; [Multipl miyelom tanılı hastada saptanan patolojik odontoid kırığı](Turkish Society of Hematology, 2017) Acar E.A.; Demirci U.; Pabuşçu Y.; Miskioğlu H.M.; Aydoğdu İ.[No abstract available]Item Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)(Elsevier Ltd, 2017) Tekgündüz E.; Demirkan F.; Vural F.; Göker H.; Özdoğu H.; Kiki İ.; Aydoğdu İ.; Kaynar L.; Erkurt M.A.; Çağırgan S.; Beşışık S.; Dağdaş S.; Koca E.; Kadıköylü G.; Gündüz E.; Yılmaz M.; Beköz H.; Ural A.U.; Baştürk A.; Arat M.; Albayrak M.; Öztürk E.; Akyol A.; Bolaman A.Z.; Nevruz O.; Özkan H.A.; Özgür G.; Altuntaş F.Autologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and/or relapsed/refractory disease settings. Although there are recently published consensus guidelines addressing critical issues regarding autologous hematopoietic progenitor cell mobilization (HPCM), mobilization strategies of transplant centers show high variability in terms of routine practice. In order to understand the current institutional policies regarding HPCM in Turkey and to obtain the required basic data for preparation of a national positional statement on this issue, Turkish Hematology Research and Education Group (ThREG) conducted a web-based HPCM survey. The survey was designed to include multiple-choice questions regarding institutional practice of HPCM in adults presenting MM, HL, and NHL. The representatives of 27 adult HCT centers participated to the study. Here we report the results of this survey shedding light on the real-world experience in Turkey in terms of autologous HPCM mobilization strategies in patients presenting with MM and lymphoma. © 2017 Elsevier LtdItem Treatment of inflammatory bowel disease by leukocytapheresis(Elsevier Ltd, 2017) Gerçeker E.; Yüceyar H.; Kasap E.; Demirci U.; Ekti B.C.; Aydoğdu İ.; Miskioğlu M.Studies about leukocytapheresis have emerged with the need of search for alternatives to conventional treatment in inflammatory bowel diseases (IBD). Leukocytapheresis is a novel non-pharmacologic approach for active ulcerative colitis (UC) and Crohn's disease (CD), in which leukocytes are mechanically removed from the circulatory system. Patients with active IBD treated with leukocytapheresis using a Cellsorba E column between 2012 and 2015, were enrolled in Turkey. In our experience, the results of leukocytapheresis therapy in 6 patients with CD and 20 patients with active UC were overviewed. Leukocytapheresis (10 sessions for remission induction therapy, 6 sessions for maintenance therapy) was applied to the patients with their concomitant medications. Intensive leukocytapheresis (≥4 leukocytapheresis sessions within the first 2 weeks) was used in 30% patients with active severe UC. The overall clinical remission rate in patients with UC was 80%, and the mucosal healing rate was 65%. Patients were followed for an average of 24 months. It was observed that clinical remission has continued in 65% of patients with UC. Mild relapse was observed in 3 patients with UC during follow up period. In 5 patients with CD significant clinical remission was achieved except only one patient. Surgical needs were disappeared in 3 patients with obstructive type Crohn's disease. Adverse events were seen in only 4.3% of 416 sessions. Any concomitant medications did not increase the incidence of adverse events. Our results indicate that leukocytapheresis is efficacious in improving remission rates with excellent tolerability and safety in patients with IBD. © 2017 Elsevier LtdItem A rare vasculitis type in a patient with acute myeloblastic leukemia: Annular leukocytoclastic vasculitis as a paraneoplastic syndrome?(Blackwell Publishing Inc., 2020) Çetinarslan T.; Türel Ermertcan A.; Aydoğdu İ.; Temiz P.[No abstract available]Item Langerhans cell histiocytosis: A rare cause of pathological rib fracture(Baycinar Medical Publishing, 2021) Yolcu A.; Tulay C.M.; Temiz P.; Aydoğdu İ.Langerhans cell histiocytosis, formerly known as histiocytosis X, represents clonal proliferations of the antigen-presenting dendritic cells, which are normally found in many organs. It is a rare disease which tends to affect children and adolescents. In particular, adult-onset type is very rare. Herein, we present a female adult diagnosed with Langerhans cell histiocytosis of the rib without any systemic involvement which was successfully treated with surgery. © 2021. All right reserved by the Turkish Society of Cardiovascular Surgery.Item Cutaneous anaplastic large-cell lymphoma with dramatic response to brentuximab vedotin; [Brentuximab vedotine dramatik yanıtlı kutanöz anaplastik büyük hücreli lenfoma](Turkish Society of Hematology, 2021) Şahin M.; Miskioğlu M.; Inanır I.; Akar H.; Neşe N.; Temiz P.; Aydoğdu İ.[No abstract available]Item Efficacy and safety of ruxolitinib in patients with myelofibrosis: A retrospective and multicenter experience in turkey(Turkiye Klinikleri, 2021) Soyer N.; Ali R.; Turgut M.; Haznedaroğlu İ.C.; Yilmaz F.; Aydoğdu İ.; Pir A.; Karakuş V.; Özgür G.; Kiş C.; Ceran F.; Ilhan G.; Özkan M.; Aslaner M.; Ince İ.; Yavaşoğlu İ.; Gediz F.; Sönmez M.; Güvenç B.; Özet G.; Kaya E.; Vural F.; Şahin F.; Töbü M.; Durusoy R.; Saydam G.Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28–87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10–40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1–55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment. © TÜBİTAK.Item Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data; [Kronik Lenfositik Lösemili Hastalarda İbrutinib Tedavisinin Etkililiği ve Güvenilirliği: Gerçek Hayat Verilerinin Retrospektif Analizi](Turkish Society of Hematology, 2021) Tombak A.; Tanrıkulu F.P.; Durusoy S.S.; Dinçyürek H.D.; Kaya E.; Ümit E.G.; Yavaşoğlu İ.; Mehtap Ö.; Deveci B.; Özcan M.A.; Terzi H.; Okay M.; Sayınalp N.; Yılmaz M.; Okan V.; Kızıklı A.; Özcan Ö.; Çetin G.; Demircioğlu S.; Aydoğdu İ.; Saydam G.; Davulcu E.A.; İlhan G.; Uçar M.A.; Özet G.; Akpınar S.; Turgut B.; Berber İ.; Kurtoğlu E.; Sönmez M.; Batur D.S.; Yıldırım R.; Özkocamaz V.; Güneş A.K.; Sahip B.; Ertop Ş.; Akay O.M.; Baştürk A.; Doğu M.H.; Akdeniz A.; Ünal A.; Seyhanlı A.; Gürkan E.; Çekdemir D.; Ferhanoğlu B.Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age ± standard deviation: 64.6±10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p<0.001, p=0.001, and p<0.001, respectively), with ECOG class 0-1 versus class 2-3 (p=0.006, p=0.011, and p=0.001, respectively), and with Rai stage 0-2 versus 3-4 (p=0.002, p=0.001, and p=0.002, respectively). No significant difference was noted in treatment response rates or survival outcome with respect to the presence of comorbidity, bulky disease, or del(17p). While 176 adverse events (AEs) were reported in 74 (54.4%) patients, 46 of those 176 AEs were grade 3-4, including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5). Conclusion: This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes. © 2021 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House.Item Acquired Hemophilia A In Adults: A Multicenter Study from Turkey(Springer, 2023) Arslan Davulcu E.; Demirci Z.; Yılmaz U.; Ar M.C.; Teke H.Ü.; Karakuş V.; Çiftçiler R.; Selim C.; Yavaşoğlu İ.; Durusoy S.S.; Okan V.; Akdeniz A.; Yolcu A.; Aydoğdu İ.; Güney T.; Yılmaz A.F.; Şahin F.Acquired hemophilia A (AHA) is a rare disease caused by autoantibodies inhibiting factor VIII (FVIII) activity. Although the conditionis usually idiopathic, there may be other underlying diseases. Treatment consists of two steps: treatment of acute bleeding and immunosuppression. In this multicenter study, we aimed to demonstrate the clinical characteristics, management details, and survival of AHA patients in Turkey. Data was collected from eleven centers in Turkey. aPTT, FVIII, FVIII inhibitor, and hemoglobin (HB) levels, mixing test results, and demographics at diagnosis, treatment information, adverse events, bleeding episodes during follow-up, relapses, and outcome were analyzed. Twenty-nine patients were analyzed (58.6% female). No underlying disorder could be detected in 14 patients. The most prevalent etiologies were pregnancy, malignancy and infections. The median FVIII activity and FVIII inhibitor titer at diagnosis were 0.7% (0.0–29.4%) and 32.6 BU (0.6–135.6 BU) respectively. Bleeding was severe in 44.8% of patients. The HB value was significantly lower in patients with severe bleeding. Most of the patients (n = 25, 86.2%) had only one bleeding episode without relapse, three patients (10.3%) had two bleeding episodes, and one patient had more than three bleedings. 21 (75%) patients received hemostatic therapy. The use of recombinant FVIIa was slightly higher than activated prothrombin complex concentrate (15 versus 10 patients). Immunosuppressive treatment was initiated in 26 (93%) patients. Regimens containing steroid, cyclophosphamide, and rituximab in different combinations were the most preferred. The median follow-up period was 13 months (2–156 months). Median overall survival was 154.97 months. Four and six-year survival were 90.9 ± 0.8% and 77.9 ± 14.1% respectively. This is a unique study that investigated the demographic characteristics, treatment approaches, and patient survival of AHA in Turkey. © 2022, The Author(s), under exclusive licence to Indian Society of Hematology and Blood Transfusion.Item The Prognostic Impact of Tumor Microenvironment and Checkpoint Blockade-Associated Molecules (PD-1, PD-L1, CD163 and CD14) in Nodal Diffuse Large B-cell Lymphoma, NOS(Springer, 2024) Atmış Ö.; Neşe N.; Aydoğdu İ.; Alaca İ.; Mavili H.S.; İşisağ A.It is aimed to determine expression of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), CD163 and CD14 in diffuse large B-cell lymphomas (DLBCL), and whether these markers may predict prognosis in DLBCL cases. A total of 52 nodal DLBCL, NOS cases with no known extranodal involvement at the time of diagnosis were evaluated. PD-1, PD-L1, CD163, and CD14 were studied by immunohistochemistry. The relationships between the results and clinical and laboratory prognostic markers were investigated. It was observed that patients with PD-1 expression < 5 positive cells/HPF had worse overall survival. No significant relationship was found between survival and PD-L1, CD163 and CD14 expressions. In addition, cases that are > 60 years of age, that have Eastern Cooperative Oncology Group (ECOG) performance score ≥ 2, stage IV disease, high International Prognostic Index score score (≥ 3), elevation of LDH, low albumin level, low hemoglobin level, low peripheral blood lymphocyte count, high peripheral blood neutrophil/lymphocyte ratio, high peripheral blood platelet/lymphocyte ratio were found to have worse overall survival. It was concluded that in patients with low number of PD-1 positive tumor-infiltrating lymphocytes have low survival rates and therefore PD-1 expression may be useful in indicating prognosis. © The Author(s), under exclusive licence to Indian Society of Hematology and Blood Transfusion 2023.Item A comparative analysis of metaheuristic algorithms for optimizing curved roof structures(Elsevier Ltd, 2024) Üstüner B.; Aydoğdu İ.; Özyürek C.; Doğan E.This article explores the optimal design of curved steel structures with a focus on minimizing their weight by determining the most suitable cross-sections. Customized optimization algorithms were developed to identify structural designs that meet safety and durability requirements, adhering to design constraints set by the ASD-AISC specification. To ensure reliable results, the study employs a variety of metaheuristic optimization methods: Biogeography-Based Optimization (BBO), Dynamic Harmony Search (DHS), Wolf Colony Algorithm (WCA), and Honey Badger Algorithm (HBA). The Honey Badger Algorithm, a relatively new addition to the field, was used for the first time in the context of structural optimization for curved roof systems. This unique approach aims to evaluate its performance in civil engineering problems and compare it with other established algorithms. The major challenges of this study lie in the inherent complexity of dome structures, which involve a large number of elements and nonlinear constraints. The subdivision of the structure into smaller groups was necessary to manage the computational load, although this introduced additional complexities. Despite these challenges, the metaheuristic methods demonstrated their robustness in addressing such intricate engineering problems. Additionally, data retrieval is facilitated through Open Application Interface (OAPI) functions, enabling seamless data transfer between SAP 2000 and Visual Basic. The study's final design example involves a dome model with 2556 elements, which was both modeled and optimized. The results demonstrate the effectiveness of these optimization algorithms in achieving structurally sound and efficient designs. The insights gained from this study contribute to our understanding of optimized cross-sections in curved steel structures, offering valuable guidance for improving structural performance and minimizing material usage. © 2024Item Clinicopathologic Spectrum of Dermatological Diseases in Patients with Acute Myeloid Leukemia (AML): A Retrospective Study in AML Patients with Cutaneous Manifestations(Springer, 2025) Çetinarslan T.; Avcı B.T.; Pehlivan F.S.; Aydoğdu İ.; Temiz P.; Ermertcan A.T.Leukemia is one of the most common hematological malignancies. Cutaneous manifestations of leukemias consist of two groups: specific and non-specific. While the drug reactions, opportunistic infections due to myelosuppression are non-specific skin findings of leukemias, leukemia cutis is a specific sign of cutaneous involvement. In this retrospective study, we included patients over the age of 18 who were diagnosed with acute myeloid leukemia (AML) and underwent histopathological examination due to dermatological complaints. A total of 21 patients were included. Histopathological examination results were consistent with myeloid sarcoma, erythema nodosum, cutaneous drug eruption, necrosis due to vascular damage, cutaneous vasculitis, graft versus host disease, Sweet syndrome and viral infection. Dermatological examination plays an important role in AML patients. Skin biopsy and immunohistochemical examination should be performed to make early diagnosis of skin metastasis of leukemias and paraneoplastic syndromes to reduce the mortality and morbidity in AML patients. © Indian Society of Hematology and Blood Transfusion 2025.Item Oral administration of ruxolitinib in psoriasis vulgaris: A case report of plaque psoriasis accompanied by myelofibrosis secondary to polisitemia vera successfully treated with oral ruxolitinib(John Wiley and Sons Inc, 2025) Çetinarslan T.; Aydoğdu İ.; Ermertcan A.T.Psoriasis is a chronic inflammatory skin disease characterized by keratinocyte hyperproliferation and immune cell infiltration. Various therapies have been discovered for psoriasis, including topical treatments, phototherapy, conventional systemic agents such as methotrexate, retinoids and ciclosporine, as well as biologics. Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibitors targeting Tumor Necrosis Factor alpha (TNF-α), interleukin (IL)-23 and IL-17 can be effective in psoriasis. Ruxolitinib is a US Food and Drug Administration-approved first-generation Janus kinase inhibitor for polycythemia vera, myelofibrosis, and acute graft-versus-host disease. Ruxolitinib cream has been investigated in various dermatologic diseases, including atopic dermatitis, vitiligo, psoriasis, and alopecia areata. However, there is limited data on the efficacy of oral ruxolitinib in patients with psoriasis vulgaris. Here, we report a patient diagnosed with myelofibrosis coexisting with psoriasis vulgaris, successfully treated with oral ruxolitinib. © 2024 Japanese Dermatological Association.